Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Endogenous IFNγ in chronic HCV genotype 4 patients treated with PEG-IFNα and ribavirin.

Sadeq R, Mohtady H, Al Badawy N, Ibrahim S, Omar AR, Husseiny MI, El Zowalaty M.

J Infect Dev Ctries. 2013 Nov 15;7(11):859-67. doi: 10.3855/jidc.2937.

2.

Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.

Jabłonowska E, Piekarska A, Koślińska-Berkan E, Omulecka A, Szymańska B, Wójcik K.

Acta Biochim Pol. 2012;59(3):333-7.

3.

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.

Itokawa N, Atsukawa M, Tsubota A, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C.

J Gastroenterol Hepatol. 2013 Mar;28(3):443-9. doi: 10.1111/jgh.12039.

PMID:
23173698
4.

Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan.

Lin JA, Chen YC, Cheng SN, Chen PJ, Chu HC, Hsieh TY, Shih YL.

J Formos Med Assoc. 2014 Oct;113(10):727-33. doi: 10.1016/j.jfma.2013.10.010.

5.

Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.

Kamal SM, Ahmed A, Mahmoud S, Nabegh L, El Gohary I, Obadan I, Hafez T, Ghoraba D, Aziz AA, Metaoei M.

Liver Int. 2011 Mar;31(3):401-11. doi: 10.1111/j.1478-3231.2010.02435.x.

PMID:
21281434
7.

Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.

Gallegos-Orozco JF, Fuentes AP, Olivera-Martinez MA, Gutiérrez-Reyes G, Cortina D, Oregel JA, Pérez-Pruna C, Sixtos MS, Cruz-Castellanos S, Soto-Ramírez LE, Rodríguez-Díaz R, Fuentes-Romero L, Gutiérrez-Ruiz MC, Kershenobich D.

Rev Invest Clin. 2003 Mar-Apr;55(2):138-42.

PMID:
12827916
8.

Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.

Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Iio S, Oshita M, Hagiwara H, Mita E, Inui Y, Hijioka T, Inada M, Tamura S, Yoshihara H, Inoue A, Imai Y, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Hayashi N, Takehara T.

J Gastroenterol. 2014 Apr;49(4):737-47. doi: 10.1007/s00535-013-0824-z.

PMID:
23689988
9.

Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.

Reddy KR, Zeuzem S, Zoulim F, Weiland O, Horban A, Stanciu C, Villamil FG, Andreone P, George J, Dammers E, Fu M, Kurland D, Lenz O, Ouwerkerk-Mahadevan S, Verbinnen T, Scott J, Jessner W.

Lancet Infect Dis. 2015 Jan;15(1):27-35. doi: 10.1016/S1473-3099(14)71002-3. Erratum in: Lancet Infect Dis. 2016 Apr;16(4):404.

PMID:
25482330
10.

Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy.

Hsu CS, Liu CH, Liu CJ, Chen CL, Lai MY, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2009;14(1):45-54.

PMID:
19320236
12.

Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin.

Oze T, Hiramatsu N, Song C, Yakushijin T, Iio S, Doi Y, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Hayashi N, Takehara T.

J Gastroenterol. 2012 Mar;47(3):334-42. doi: 10.1007/s00535-011-0498-3.

PMID:
22109353
13.

Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.

Tohra SK, Taneja S, Ghosh S, Sharma BK, Duseja A, Dhiman RK, Das A, Chawla YK.

Dig Dis Sci. 2011 Aug;56(8):2449-55. doi: 10.1007/s10620-011-1770-3.

PMID:
21706207
14.

Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.

Alsaran K, Sabry A, Shaheen N.

Int Urol Nephrol. 2011 Sep;43(3):865-73. doi: 10.1007/s11255-010-9756-1.

PMID:
20490669
15.
16.
17.

Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.

Derbala M, Amer A, Bener A, Lopez AC, Omar M, El Ghannam M.

J Viral Hepat. 2005 Jul;12(4):380-5.

PMID:
15985008
18.

An early viral response to standard interferon-alpha identifies resistance to combination therapy with peginterferon and ribavirin in patients infected by HCV genotype 1.

Toyoda H, Kumada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Takagi M, Hiramatsu T, Hosokawa T, Arakawa T, Fujimori M.

J Med Virol. 2010 Sep;82(9):1537-44. doi: 10.1002/jmv.21858.

PMID:
20648607
19.

Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.

Jessner W, Stauber R, Hackl F, Datz C, Watkins-Riedel T, Hofer H, Gangl A, Kessler H, Ferenci P.

J Viral Hepat. 2003 Jan;10(1):37-42.

PMID:
12558910
20.

Supplemental Content

Support Center